These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12127537)

  • 21. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
    Banoglu E; Çalişkan B; Luderer S; Eren G; Özkan Y; Altenhofen W; Weinigel C; Barz D; Gerstmeier J; Pergola C; Werz O
    Bioorg Med Chem; 2012 Jun; 20(12):3728-41. PubMed ID: 22607880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, molecular docking and biological evaluation of some benzimidazole derivatives as potent pancreatic lipase inhibitors.
    Menteşe E; Yılmaz F; Emirik M; Ülker S; Kahveci B
    Bioorg Chem; 2018 Feb; 76():478-486. PubMed ID: 29306066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships.
    Saify ZS; Azim MK; Ahmad W; Nisa M; Goldberg DE; Hussain SA; Akhtar S; Akram A; Arayne A; Oksman A; Khan IA
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1282-6. PubMed ID: 22204908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and molecular modeling of new benzimidazoles as glutathione S-transferase inhibitors and anticancer agents.
    Abd El-Karim SS; Anwar MM; Zaki ER; Elseginy SA; Nofal ZM
    Future Med Chem; 2018 Jan; 10(2):157-181. PubMed ID: 29235906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.
    Bilodeau MT; Cunningham AM; Koester TJ; Ciecko PA; Coll KE; Huckle WR; Hungate RW; Kendall RL; McFall RC; Mao X; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2485-8. PubMed ID: 12852948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
    Dublanchet AC; Ducrot P; Andrianjara C; O'Gara M; Morales R; Compère D; Denis A; Blais S; Cluzeau P; Courté K; Hamon J; Moreau F; Prunet ML; Tertre A
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3787-90. PubMed ID: 16002291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and antitumor activity of novel benzimidazole-5-carboxylic acid derivatives and their transition metal complexes as topoisomerease II inhibitors.
    Galal SA; Hegab KH; Hashem AM; Youssef NS
    Eur J Med Chem; 2010 Dec; 45(12):5685-91. PubMed ID: 20884089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
    Da Settimo F; Primofiore G; Da Settimo A; La Motta C; Taliani S; Simorini F; Novellino E; Greco G; Lavecchia A; Boldrini E
    J Med Chem; 2001 Dec; 44(25):4359-69. PubMed ID: 11728182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.
    Wan H; Huynh T; Pang S; Geng J; Vaccaro W; Poss MA; Trainor GL; Lorenzi MV; Gottardis M; Jayaraman L; Purandare AV
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5063-6. PubMed ID: 19632837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of novel benzoheterocyclic derivatives as human acrosin inhibitors by scaffold hopping.
    Chen Q; Tian W; Han G; Qi J; Zheng C; Zhou Y; Ding L; Zhao J; Zhu J; Lv J; Sheng C
    Eur J Med Chem; 2013 Jan; 59():176-82. PubMed ID: 23220646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of a benzimidazole series as the first highly potent and selective ACSL1 inhibitors.
    Hayashi K; Kondo N; Omori N; Yoshimoto R; Hato M; Shigaki S; Nagasawa A; Ito M; Okuno T
    Bioorg Med Chem Lett; 2021 Feb; 33():127722. PubMed ID: 33285268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Synthesis and bioactivity of N- [4- ( benzimidazole-2-thio) phenyl] -N'-alkyl guanidine derivatives].
    Xu YG; Xing AM; Hong M; Sun XY
    Yao Xue Xue Bao; 2007 Feb; 42(2):152-6. PubMed ID: 17518042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors.
    Cole AG; Bohnstedt AC; Paradkar V; Kingsbury C; Quintero JG; Park H; Lu Y; You M; Neagu I; Diller DJ; Letourneau JJ; Shao Y; James RA; Riviello CM; Ho KK; Lin TH; Wang B; Appell KC; Sills M; Quadros E; Kimble EF; Ohlmeyer MH; Webb ML
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6788-92. PubMed ID: 19836234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
    Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
    Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substituted 2,5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity.
    Kim JS; Gatto B; Yu C; Liu A; Liu LF; LaVoie EJ
    J Med Chem; 1996 Feb; 39(4):992-8. PubMed ID: 8632422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, combinatorial chemical synthesis and in vitro characterization of novel urea based gelatinase inhibitors.
    Zhang Y; Li D; Houtman JC; Witiak DT; Seltzer J; Bertics PJ; Lauhon CT
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2823-6. PubMed ID: 10522699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective inhibition of heme oxygenase-2 activity by analogs of 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole (clemizole): Exploration of the effects of substituents at the N-1 position.
    Vlahakis JZ; Vukomanovic D; Nakatsu K; Szarek WA
    Bioorg Med Chem; 2013 Nov; 21(21):6788-95. PubMed ID: 24021581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
    Lewis JA; Scott SA; Lavieri R; Buck JR; Selvy PE; Stoops SL; Armstrong MD; Brown HA; Lindsley CW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1916-20. PubMed ID: 19268584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.